Artiva Biotherapeutics ARTV
NASDAQ ARTV
$4.07 +0.01 (+0.25%)
At close: Nov 11, 2026 · 4:00 PM EST

Artiva Biotherapeutics (ARTV) Return on Sales [ROS] (2023 - 2024)

Updated

Artiva Biotherapeutics (ARTV) reported Return on Sales [ROS] of -26806.37% for Q4 2024, down 26297.01 percentage points from -509.36% a year earlier and down 24461.62 percentage points from the prior quarter.

Analysis

Artiva Biotherapeutics (ARTV) Return on Sales [ROS] (2023 - 2024) Analysis & Trends

For FY2024, Artiva Biotherapeutics posted Return on Sales [ROS] of -26805.58%, down 26714.00 percentage points from FY2023.

  • By year, Return on Sales [ROS] came in at -91.58% in FY2023.
  • Per Business Quant data, the three quarters before Q4 2024 came in at -2344.75% (Q3 2024), -108.83% (Q2 2024) and -5773.71% (Q1 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Artiva Biotherapeutics 200.70 Mn -118.40 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -26,806.37%
Sep 30, 2024 -2,344.75%
Jun 30, 2024 -108.83%
Mar 31, 2024 -5,773.71%
Dec 31, 2023 -509.36%
Sep 30, 2023 40.56%
Jun 30, 2023 -338.12%
API Access

Artiva Biotherapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ARTV&period=max&api_key=YOUR_API_KEY